SHANGHAI, Aug. 27, 2015
/PRNewswire/ -- WuXi PharmaTech (Cayman) Inc.
(NYSE: WX), a leading
open-access R&D capability and technology platform company
serving the pharmaceutical, biotechnology, and medical device
industries, today announced that its small-molecule
process development and manufacturing subsidiary Shanghai SynTheAll
Pharmaceutical Co., Ltd. (STA) received its first approval from the
Japan PMDA for the manufacture of the GMP intermediate of a branded
commercial drug in July. STA is now the only Chinese contract
manufacturing organization to have received approval to supply
active pharmaceutical ingredients (APIs) and GMP intermediates for
branded commercial drugs from regulatory agencies in the United States, Canada, the European Union, Switzerland, China, Japan,
Australia, and New Zealand.
STA's integrated platform of services, extending from process
research to research manufacturing to commercial manufacturing,
helps clients move their new chemical entities through preclinical
and clinical development to global commercial launch.
"I'm very proud of our track record in securing approvals from
global regulatory agencies and the added confidence these successes
bring to our partners," said Dr. Minzhang Chen, CEO of STA.
"This favorable outcome further demonstrates that STA's
facilities, processes, and people are world-class and of the
highest quality," said Dr. Ge Li,
chairman and CEO of WuXi PharmaTech. "We look forward to
expanding these capabilities with our new facilities under
construction in Changzhou to
better serve our partners."
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and
technology platform company serving the pharmaceutical,
biotechnology, and medical device industries, with operations in
China and the United States. As a research-driven and
customer-focused company, WuXi PharmaTech provides a broad and
integrated portfolio of services throughout the drug and medical
device R&D process. WuXi is also building a platform to provide
clinical diagnostic services directly to physicians and their
patients globally. WuXi PharmaTech's services are designed to
assist its global partners in shortening the cycle and lowering the
cost of drug and medical device R&D. WuXi PharmaTech's
operating subsidiaries are known as WuXi AppTec. For more
information, please visit: http://www.wuxiapptec.com.
For more information, please contact:
Ronald Aldridge (for
investors)
LaVoieHealthScience
+1-617-374-8800 x109
+1 617-792-2459
ir@wuxiapptec.com
Aaron Shi (for the media)
Director, Corporate Communications
WuXi PharmaTech
+86-21-5046-4362
pr@wuxiapptec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/wuxi-pharmatechs-sta-subsidiary-receives-first-approval-from-japanese-regulatory-authorities-300133006.html
SOURCE WuXi PharmaTech (Cayman) Inc.